|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
Acquired by a private equity firm in 2021
|
|
gptkbp:business_model
|
partnerships and collaborations
|
|
gptkbp:can_lead_to
|
gptkb:IMGN151
gptkb:IMGN632
|
|
gptkbp:ceo
|
gptkb:Mark_Enyedy
|
|
gptkbp:clinical_trial
|
gptkb:Oncology
ovarian cancer
ongoing
Phase 1
Phase 2
Phase 3
diverse patient populations
published in peer-reviewed journals
multiple sites globally
various phases of development
|
|
gptkbp:collaboration
|
gptkb:Johns_Hopkins_University
gptkb:University_of_California,_San_Francisco
with academic institutions
|
|
gptkbp:collaborations
|
with pharmaceutical companies
with research institutions
|
|
gptkbp:community_engagement
|
involvement in cancer awareness initiatives
|
|
gptkbp:employees
|
approximately 200
|
|
gptkbp:focus
|
cancer therapeutics
|
|
gptkbp:focus_area
|
immuno-oncology
|
|
gptkbp:founded
|
gptkb:1981
|
|
gptkbp:funding
|
from government grants
from private investors
|
|
gptkbp:future_plans
|
expansion of drug pipeline
|
|
gptkbp:has_advisory_board
|
composed of industry experts
|
|
gptkbp:headquarters
|
gptkb:Waltham,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Immuno Gen
|
|
gptkbp:instruction_set
|
multiple drug candidates
|
|
gptkbp:invention
|
multiple patents in drug development
|
|
gptkbp:investment
|
Venture capital firms
engagement with shareholders
|
|
gptkbp:market_cap
|
approximately $1 billion (2021)
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:partnerships
|
with biotech firms
|
|
gptkbp:publications
|
numerous publications in journals
|
|
gptkbp:regulatory_compliance
|
FDA approval for certain drugs
|
|
gptkbp:related_products
|
gptkb:Mirvetuximab_soravtansine
gptkb:Trastuzumab_emtansine
|
|
gptkbp:research_and_development
|
significant investment
|
|
gptkbp:research_areas
|
oncology
targeted delivery of drugs
|
|
gptkbp:research_focus
|
targeted cancer therapies
|
|
gptkbp:revenue
|
$50 million (2020)
|
|
gptkbp:stock_symbol
|
IMGN
|
|
gptkbp:technology
|
Antibody-drug conjugates
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.immunogen.com
|
|
gptkbp:bfsParent
|
gptkb:Ariad_Pharmaceuticals
gptkb:Agenus_Inc.
|
|
gptkbp:bfsLayer
|
5
|